|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
One of 2 lymphoma immunoglobulin test cases bound the E2 protein in a manner identical to a bona fide human anti-E2 antibody.
|
11739181 |
2001 |
|
Autoimmune thyroiditis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that HCV E2 protein binding to CD81 expressed on thyroid cells activates a cascade of inflammatory responses that can trigger autoimmune thyroiditis in susceptible individuals.
|
27860532 |
2017 |
|
Azoospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A functional variant in the UBE2B gene promoter is associated with idiopathic azoospermia.
|
26223869 |
2015 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
β-catenin and Rad6B colocalize in breast carcinoma and coimmunoprecipitate from MDA-MB-231 cells.
|
22705350 |
2012 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Whereas normal breast cells express low levels of Rad6B, increases in Rad6B expression occur in hyperplasia with overexpression in breast carcinomas.
|
17050667 |
2006 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
HPV E2 protein is considered a tumor suppressor in the context of high-risk HPV-induced transformation and therefore, to explore the mechanisms involved in the downregulation of ASncmtRNAs during tumorigenesis, we studied human foreskin keratinocytes (HFK) transduced with lentiviral-encoded HPV-18 E2.
|
30595560 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The human papillomavirus (HPV) E2 protein is a transcriptional repressor of the oncogenes E6/E7 and loss of E2 function is considered a key step in carcinogenesis.
|
25731880 |
2015 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Hybridization with a probe specific for mRNA with a coding potential for a full-length E2 protein yielded weak signals in both carcinomas.
|
8386138 |
1993 |
|
cervical cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results suggest that local delivery of VP22-E2 fusion proteins could be used to treat cervical cancer and other HPV-associated diseases.
|
14709162 |
2004 |
|
cervical cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
|
16454648 |
2006 |
|
Cervical Intraepithelial Neoplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The human papillomavirus type 16 (HPV-16) status of 43 cervical biopsies, which had been characterized histologically as normal, various grades of cervical intraepithelial neoplasia (CIN) and invasive squamous cell carcinoma, was examined by using (i) a novel antibody against the HPV-16 E2 protein, (ii) sensitive HPV-16 DNA in situ hybridization and (iii) microdissection/PCR for the E2 ORF.
|
10859389 |
2000 |
|
Cervical Intraepithelial Neoplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Human papillomaviruses (HPV) are strongly associated with cervical intraepithelial neoplasia (CIN) and invasive cancer mainly through the action of the E6 and E7 viral proteins, transcription of which is down-regulated by the E2 protein.
|
11308254 |
2001 |
|
Cervical Intraepithelial Neoplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We found that serum IgA levels against the E2 protein were elevated in CIN patients relative to normal control subjects but were not elevated in cervical cancer patients.
|
9099962 |
1997 |
|
Cervical intraepithelial neoplasia grade 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The data indicate that E2 protein expression is highest in koilocytes in lower-grade CIN (I), but decreases with increasing grade, whereas the detection of HPV DNA is delayed until CIN I/II, rising to the highest levels in carcinoma cells.
|
10859389 |
2000 |
|
Cervix carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
A hallmark of HPV-associated cervical carcinoma is loss of the expression of the viral E2 protein, often by disruption of E2-encoding gene.
|
14871818 |
2004 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Thus, a number of cervical carcinoma cell lines are remarkably sensitive to growth inhibition by the E2 protein.
|
8389903 |
1993 |
|
Cervix carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Using new polyclonal antibodies against the HPV16 E2 protein, we showed that E2 is expressed at various precursor stages of cervical carcinoma by immunohistochemistry on paraffin-embedded clinical samples.
|
20530671 |
2010 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
|
16454648 |
2006 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results suggest that local delivery of VP22-E2 fusion proteins could be used to treat cervical cancer and other HPV-associated diseases.
|
14709162 |
2004 |
|
Cervix carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The HPV16 E2 protein plays an important role in tumourigenicity of cervical carcinoma.
|
30008422 |
2018 |
|
Chikungunya Fever
|
0.050 |
Biomarker
|
disease |
BEFREE |
Here we report cloning, expression and purification methods for obtaining a truncated 37kDa Chikungunya E2 protein at a high yield of 65-70mg/l.
|
27180040 |
2016 |
|
Chikungunya Fever
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Identification of Functional Determinants in the Chikungunya Virus E2 Protein.
|
28114368 |
2017 |
|
Chikungunya Fever
|
0.050 |
Biomarker
|
disease |
BEFREE |
A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
|
25905779 |
2015 |
|
Chikungunya Fever
|
0.050 |
Biomarker
|
disease |
BEFREE |
Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model.
|
24239837 |
2013 |
|
Chikungunya Fever
|
0.050 |
Biomarker
|
disease |
BEFREE |
Conformational changes in Chikungunya virus E2 protein upon heparan sulfate receptor binding explain mechanism of E2-E1 dissociation during viral entry.
|
31167876 |
2019 |